Evidence map›Paper›PMID 41942450›Full record

ArticleNature communications2026

Structural and mechanistic basis for antibody neutralization of the measles fusion protein.

Dawid S Zyla, Roberta Della Marca, Davide Lacarbonara, Gele Niemeyer, Gillian Zipursky, Laura Di Clemente, Mare H L Verbruggen, Laura L A van Dijk, Oscar Martinez Ceh, Gabriella Jonathan-Trakht and 14 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Dawid S Zyla *Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-8471-469X
Roberta Della Marca *Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID http://orcid.org/0009-0000-5955-4495
Davide LacarbonaraCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Gele NiemeyerCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Gillian ZipurskyCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Laura Di ClementeCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID http://orcid.org/0009-0001-7849-9484
Mare H L VerbruggenDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
Laura L A van DijkDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0001-5716-2738
Oscar Martinez CehCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0009-0001-7242-8319
Gabriella Jonathan-TrakhtDepartment of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Gavreel KalantarovDepartment of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Marissa AccianiCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Giulia LaterzaCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID http://orcid.org/0000-0003-2622-9631
Dariia VyshenskaDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Cameron LeedaleDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Emily PawlackDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0009-0003-0880-4994
Kathryn M HastieCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3406-1210
Branka HorvatImmunobiology of Viral Infections, CIRI, International Center for Infectiology Research, INSERM U1111, CNRS UMR5308, University Lyon 1, ENS de Lyon, Lyon, France.ORCID http://orcid.org/0000-0003-0578-7765
Rik L de SwartDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0003-3599-8969
Rory D de VriesDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0003-2817-0127
Alexander L GreningerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-7443-0527
Stefan NiewieskDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA. erica@lji.org.ORCID http://orcid.org/0000-0002-1206-7451
Matteo PorottoCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. mp3509@columbia.edu.ORCID http://orcid.org/0000-0003-3866-9220

Funding

Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPPU19AI181984 · NIAID · WASHINGTON UNIVERSITY · PI MCELROY, ANITA K · 2024 to 2024
$44.1M
Design of fusion inhibitors to block measles host-to-host infectionR01AI176833 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Matteo Porotto · 2023 to 2026
$2.8M
Mechanisms of measles virus CNS adaptationR01NS091263 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI POROTTO, MATTEO · 2015 to 2019
$1.9M
Development of therapeutic fusion inhibitor peptides for Measles encephalitisR01NS105699 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2018 to 2022
$1.8M
Thermostable measles fusion glycoprotein as a new vaccine strategyR56AI183536 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO, SAPHIRE, ERICA OLLMANN · 2024 to 2024
$884k
Thermostable measles fusion glycoprotein as a new vaccine strategyR01AI190902 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Matteo Porotto, Erica Ollmann Saphire · 2026 to 2026
$883k
Passive immunotherapy for measles infectionR01AI195589 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Matteo Porotto, Erica Ollmann Saphire · 2026 to 2026
$855k
What is the human antibody response to measles virus vaccination?R21AI180456 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2024 to 2025
$496k
NIAID NIH HHS R01 AI176833NIAID NIH HHS U19 AI181984U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI176833U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI190902U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI195589U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21AI180456U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R56AI183536U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI181984U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS091263U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS105699
6 · The paper itself

Abstract

Measles virus (MeV) is a highly contagious pathogen and a major global health threat. Resurgent infections, driven by insufficient vaccine coverage, waning herd immunity, and the vulnerability of immunocompromised populations, highlight the urgent need for effective countermeasures. While most vaccine-elicited antibodies target the hemagglutinin (H) protein, antibodies against the fusion (F) protein are also potent inhibitors. However, the specific target sites on this class I fusion protein, which undergoes dramatic conformational changes during entry, remain insufficiently characterized. Here, we characterize four mAbs targeting distinct F conformations. Structural analyses map antibody interactions, revealing that three neutralizing mAbs recognize the metastable prefusion conformation, while a non-neutralizing mAb binds only the post-triggered state. Biophysical and functional assays define distinct mechanisms of action: neutralization occurs either by stabilizing the prefusion protein or by preventing the extended intermediate from completing fusion. Uniquely, we detect a novel mechanism where an antibody prematurely triggers F activation but blocks the subsequent refolding required for viral entry. These findings provide the first detailed mapping of neutralizing epitopes on MeV F, establishing a framework for the rational design of F-targeted interventions.

Indexed as

Antibodies, NeutralizingAntibodies, ViralMeasles virusViral Fusion ProteinsAnimalsAntibodies, MonoclonalEpitopesHumansMeaslesModels, MolecularProtein ConformationVirus InternalizationAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesViral Fusion Proteins

Identifiers

PMID41942450
PMCPMC13230913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.